# Third Quarter 2024 Business Update & Financial Results Conference Call

AMARIN®

October 30, 2024

# Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, and guidance.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

**THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.**

# Today's Agenda

01

## STATE OF THE BUSINESS: AN UPDATE

Aaron Berg, President & CEO

02

## THIRD QUARTER 2024 FINANCIAL RESULTS

Peter Fishman, Vice President, Global Controller

03

## CLOSING REMARKS & Q&A

Aaron Berg, President & CEO

# 01 STATE OF THE BUSINESS: AN UPDATE



Aaron Berg
President & CEO

# VAZKEPA / VASCEPA HAS SIGNIFICANT VALUE GLOBALLY

- Large Global Burden of Disease and Need for CV Risk Reduction
- Proven Efficacy and Safety, Strong KOL and Scientific Guideline Support
- US Success of >200K Prescribers, >25M Prescriptions and Cumulative Sales of ~$3.2Bn Since Launch (2013)
- Broad EU Opportunity with Significant IP to 2039 Supported by Historical U.S. Growth Analogue and Powerful REDUCE-IT Data
- Durable Cash Flow Generation from VASCEPA Brand Tail and Growing ROW Partnership Revenue
- Continuing to Grow ROW Partnerships, Regulatory Approvals and Revenue

Evaluate every opportunity

**TO MAXIMIZE THE IMPACT OF VAZKEPA/VASCEPA**

for millions of patients globally

# YEAR-TO-DATE 2024 OPERATIONAL HIGHLIGHTS & ONGOING PRIORITIES

AMARIN CONTINUES TO MAKE PROGRESS ACROSS ALL ASPECTS OF OUR BUSINESS OPERATIONS AND ARE EXECUTING AS PLANNED AGAINST OUR STRATEGIC PRIORITIES

## EUROPE

**PRIORITIES:**

- Accelerate revenue growth in Europe in key launched markets.
- Secure and advance pricing and reimbursement processes in additional key markets.

**YTD HIGHLIGHTS:**

✓ New IP granted, extending VAZKEPA exclusivity in Europe until 2039.

✓ Spain, UK & CEE continue to power early European growth.

✓ Secured pricing & reimbursement in Portugal, Greece; continued progress with pricing and reimbursement authorities in Italy.

## REST OF WORLD

**PRIORITIES:**

- Support partner efforts to accelerate revenues in key launch markets
- Advance pricing and reimbursement processes in key markets.

**YTD HIGHLIGHTS:**

✓ Amarin's partner EDDINGPHARM received regulatory approval for VASCEPA for cardiovascular risk reduction indication in China; EDDING advancing efforts for NRDL listing.

✓ Amarin's partner CSL Seqirus secured PBS price listing for VAZKEPA in Australia.

## U.S.

**PRIORITIES:**

- Maintain IPE market share leadership (~50%), profitability continuing to adapt to dynamic market conditions.

**YTD HIGHLIGHTS:**

✓ Continuing to retain IPE market share leadership in the U.S., despite additional generic competition.

✓ Advancing plans to launch authorized generic.

## R&D/MEDICAL

**PRIORITIES:**

- Continue to advance REDUCE-IT, EPA data; 3 accepted abstracts at American Heart Association Scientific Sessions in November.

**YTD HIGHLIGHTS:**

✓ >25 Additional Abstracts & Publications Supporting VASCEPA/VAZKEPA; >200 Educational Initiatives Executed Across Europe; Strong Presence at 4 Major Congresses.

# 02 THIRD QUARTER 2024 FINANCIAL RESULTS

Peter Fishman

Vice President, Global Controller

# Q3 2024 P&L HIGHLIGHTS

### Q3 '24 Total Revenue of $42.3M

- USA Revenue: $30.6 million; ~30% reduction vs. Q2 2024 due to lower NSP and volume
- European Revenue: $4.3 million; ~19% increase vs. Q2 2024 driven by increasing revenues from key markets
- ROW Revenue: $6.9M

### Q3 '24 Operating Expenses

- ~$10M reduction in Total Operating Expenses Q3 '24 vs. Q3 '23
- Continued focus on cost optimization efforts across the business






# CONTINUED FOCUS ON MAINTAINING CASH POSITION TO FUND ONGOING OPERATIONS; EXEMPLIFIES COMPANY'S STRONG CAPITAL STRUCTURE

***Strong Cash Position; Nine Consecutive Quarters of Positive/Neutral Cash Balance***




**Third Quarter 2024**

- Cash Balance of $306M as of 9/30/24; no debt
- Inventory draw down continues alongside progress renegotiating supply purchase agreements
- Continued focus on expense optimization across the business has bolstered cash position

# 03 CLOSING REMARKS & Q&A



Aaron Berg
President & CEO

# Q3 2024 RECAP

Balance sheet provides foundation to support ongoing business operations and **execution of expansion plans**

US market remains source of **strong cash flow** reflecting sustained high market share in the face of evolving landscape

Scientific community remains **significant and broadly diverse advocates** of IPE, EPA and the impact on CVRR and other measures contributing to CVD

Company remains committed to **maintaining NASDAQ listing**

Europe and RoW, which symbolize the dual pronged global expansion strategy for VASCEPA/VAZKEPA, continue to **evolve and build momentum**, representing sources of potential **long-term growth** (i.e., Europe IP runway extended to 2039)

Management and Board are focused on all options to **maximize shareholder value**, including ways to optimize the **significant opportunity in Europe**

**CVD remains #1 killer worldwide**[1], underscoring the unequivocal global unmet need for differentiated and impactful treatment paradigms

1. World Heart Report 2023: Confronting the World's Number One Killer. Geneva, Switzerland. World Heart Federation. 2023 (https://world-heart-federation.org/wp-content/uploads/World-Heart-Report-2023.pdf).

# Q&A

Vascepa®
(icosapent ethyl)

Vazkepa®
(icosapent ethyl)

# THANK YOU

AMARIN®